MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Dynavax Technologies Corporation Total Liabilities 2011-2026 | DVAX
Annual Total Liabilities Dynavax Technologies Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 389 M | 375 M | 405 M | 817 M | 295 M | 271 M | 148 M | 19.2 M | 20.5 M | 29.6 M | 37.8 M | 18.3 M | 24.9 M | 34.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 817 M | 18.3 M | 206 M |
Quarterly Total Liabilities Dynavax Technologies Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 412 M | 424 M | 415 M | 389 M | 381 M | 373 M | 368 M | 375 M | 368 M | 359 M | 406 M | 405 M | 499 M | - | 721 M | 817 M | 852 M | 565 M | 390 M | 295 M | 295 M | 295 M | 295 M | 271 M | 271 M | 271 M | 271 M | 148 M | 148 M | 148 M | 148 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 20.5 M | 20.5 M | 20.5 M | 20.5 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 34.2 M | 34.2 M | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 852 M | 18.3 M | 215 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
390 M | $ 3.52 | -0.85 % | $ 1.05 B |  Canada |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
AC Immune SA
ACIU
|
119 M | $ 3.09 | -6.93 % | $ 229 M |  Schweiz |
 |
Adagene
ADAG
|
38.7 M | $ 3.94 | 0.77 % | $ 222 M |  China |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M | China |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
440 M | $ 4.01 | -2.2 % | $ 105 M | Schweiz |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
1.47 B | $ 227.41 | -0.29 % | $ 5 B |  Danmark |
 |
Aileron Therapeutics
ALRN
|
7.8 M | - | 10.36 % | $ 9.8 M | USA |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Aptorum Group Limited
APM
|
4.35 M | $ 0.78 | -0.41 % | $ 4.25 M | China |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
argenx SE
ARGX
|
704 M | $ 684.77 | -3.01 % | $ 25 B |  Niderland |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.5 | 4.78 % | $ 8.42 B |  Australia |
 |
Autolus Therapeutics plc
AUTL
|
355 M | $ 1.45 | -3.97 % | $ 370 M | Britain |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
42.3 M | $ 14.11 | -2.76 % | $ 207 M | USA |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
BioCardia
BCDA
|
4.59 M | $ 1.23 | -3.91 % | $ 26.1 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | USA |
 |
BioNTech SE
BNTX
|
2.76 B | $ 90.0 | -5.12 % | $ 27.2 B | Germany |
 |
Aptose Biosciences
APTO
|
14.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Baudax Bio
BXRX
|
34.3 M | - | 0.59 % | $ 63 K | USA |
 |
Cara Therapeutics
CARA
|
68.8 M | - | -3.03 % | $ 260 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 3.44 | 0.29 % | $ 7.49 B |  Israel |
 |
Arcturus Therapeutics Holdings
ARCT
|
57.2 M | $ 6.55 | 2.5 % | $ 179 M | Israel |
 |
Catalyst Biosciences
CBIO
|
23.8 M | $ 10.35 | -6.76 % | $ 925 M | USA |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 8.22 | -0.72 % | $ 1.36 B | Britain |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Athira Pharma
ATHA
|
13.9 M | - | - | $ 269 M | USA |
 |
Athersys
ATHX
|
28.4 M | - | 3.77 % | $ 22.4 M | USA |